PRKDC and neoplasm: While some preliminary results indicate that inhibition of DNA-PKcs by NU7026 sensitizes UM cell lines for the topoisomerase I inhibitor, Topotecan, studies on cervical and breast cancer cells, as well as on lung cancer cells, have shown that this treatment sensitizes tumor cells to radiation treatment [79,80].